AstraZeneca, J&J Resume US COVID-19 Vaccine Trials
U.S. Food and Drug Administration authorized the restart after reviewing all safety data
Immunization
MPR Weekly Dose Podcast Episode 55
Results from the survey assessing willingness to receive a COVID vaccine; Dr. Fauci shares that he is ‘cautiously optimistic’ a vaccine could arrive before year’s end; And the breaking news that remdesivir (Veklury) has gained FDA approval.
Moderna: 30,000 Participants Enrolled in COVID-19 Vaccine Trial
The trial is investigating the efficacy, safety, and immunogenicity of mRNA-1273 at the 100mcg dose.
Fauci ‘Cautiously Optimistic’ for COVID-19 Vaccine by Year’s End
Fauci was speaking at a virtual meeting of the Infectious Diseases Society of America.c
Survey Reveals Factors Contributing to COVID-19 Vaccine Acceptance
To estimate the association between attribute level and probability of choosing and receiving a vaccine, the study authors calculated the average marginal component effects sizes as well as marginal means.
Novel Pneumococcal Conjugate Vaccine Immunogenic in Phase 3 Trials
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
Scientists to Infect Volunteers With COVID-19 in Challenge Trial
Challenge trials have long history, going back to development of smallpox vaccine in 1796.
No Pfizer COVID-19 Vaccine Expected Before Election
Company has reversed its previous claims that it would apply for the approval in October.
Second COVID-19 Vaccine Trial Paused for Unexplained Illness
Johnson & Johnson stopped its COVID-19 vaccine trial, which began phase 3 testing last month.
Emergency Use Authorization Guidance Issued for COVID-19 Vaccines
Data from phase 3 studies should include a median follow-up duration of at least 2 months after completion of the full vaccination regimen.
